Evidence map›Paper›PMID 31547056›Full record

ArticleInternational journal of molecular sciences2019

Platelet-Derived Growth Factor Receptor and Ionizing Radiation in High Grade Glioma Cell Lines.

Oana Alexandru, Ani-Simona Sevastre, Juan Castro, Stefan-Alexandru Artene, Daniela Elise Tache, Oana Stefana Purcaru, Veronica Sfredel, Ligia Gabriela Tataranu, Anica Dricu

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 27 citations in OpenAlex.

  1. Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Therapeutic Options in Neuro-Oncology.International journal of molecular sciences · 2022
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. ELTD1-An Emerging Silent Actor in Cancer Drama Play.International journal of molecular sciences · 2021
    Review
  17. Updated Insights on EGFR Signaling Pathways in Glioma.International journal of molecular sciences · 2021
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Oana AlexandruDepartment of Neurology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. oanale@hotmail.com.
Ani-Simona SevastreDepartment of Pharmacological Technology, Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. anifetea_umf@yahoo.com.ORCID 0000-0003-1782-2783
Juan CastroKarolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska University Hospital, Z1:00, 171 76 Stockholm, Sweden. juan.castro@kusko.org.
Stefan-Alexandru ArteneDepartment of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. stefan.artene@yahoo.com.
Daniela Elise TacheDepartment of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. dodolita@yahoo.it.
Oana Stefana PurcaruDepartment of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. stoapo@yahoo.com.
Veronica SfredelDepartment of Physiology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. veronicasfredel@yahoo.com.
Ligia Gabriela TataranuDepartment of Neurosurgery, "Bagdasar-Arseni" Emergency Hospital, Soseaua Berceni 12, 041915 Bucharest, Romania. ttranu@gmail.com.
Anica DricuDepartment of Biochemistry, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, Str. Petru Rares nr. 2-4, 710204 Craiova, Romania. anica.dricu@live.co.uk.
University of Medicine and Pharmacy of Craiova · ROClinical Emergency Hospital Bucharest · ROKarolinska University Hospital · SE

Funding

4-Partnerships in priority areas, CNMP-ANCS Bucharest grant 41-063Fifth Framework Programme QLGA-CT-2000-60005
6 · The paper itself

Abstract

Treatment of high grade gliomas (HGGs) has remained elusive due to their high heterogeneity and aggressiveness. Surgery followed by radiotherapy represents the mainstay of treatment for HGG. However, the unfavorable location of the tumor that usually limits total resection and the resistance to radiation therapy are the major therapeutic problems. Chemotherapy with DNA alkylating agent temozolomide is also used to treat HGG, despite modest effects on survival. Disregulation of several growth factor receptors (GFRs) were detected in HGG and receptor amplification in glioblastoma has been suggested to be responsible for heterogeneity propagation through clonal evolution. Molecularly targeted agents inhibiting these membrane proteins have demonstrated significant cytotoxicity in several types of cancer cells when tested in preclinical models. Platelet-derived growth factor receptors (PDGFRs) and associated signaling were found to be implicated in gliomagenesis, moreover, HGG commonly display a Platelet-derived growth factor (PDGF) autocrine pathway that is not present in normal brain tissues. We have previously shown that both the susceptibility towards PDGFR and the impact of the PDGFR inactivation on the radiation response were different in different HGG cell lines. Therefore, we decided to extend our investigation, using two other HGG cell lines that express PDGFR at the cell surface. Here, we investigated the effect of PDGFR inhibition alone or in combination with gamma radiation in 11 and 15 HGG cell lines. Our results showed that while targeting the PDGFR represents a good means of treatment in HGG, the combination of receptor inhibition with gamma radiation did not result in any discernable difference compared to the single treatment. The PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways are the major signaling pathways emerging from the GFRs, including PDGFR. Decreased sensitivity to radiation-induced cell death are often associated with redundancy in these pro-survival signaling pathways. Here we found that Phosphoinositide 3-kinases (PI3K), Extracellular-signal-regulated kinase 1/2 (ERK1/2), or c-Jun N-terminal kinase 1/2 (JNK1/2) inactivation induced radiosensitivity in HGG cells.

Indexed as

GliomaAutocrine CommunicationCell Line, TumorGamma RaysHumansMAP Kinase Signaling SystemNeoplasm ProteinsPlatelet-Derived Growth FactorReceptors, Platelet-Derived Growth FactorNeoplasm ProteinsPlatelet-Derived Growth FactorReceptors, Platelet-Derived Growth Factorhigh grade gliomaPlatelet-derived growth factor receptor (PDGFR)radiotherapy

Identifiers

PMID31547056
PMCPMC6802357
OpenAlexW2974686203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.